The present invention relates to a composition for the cryopreservation of myocardial cells, the composition comprising BLEB and/or PAB (or a physiologically acceptable salt thereof) and an antifreeze agent. The present invention further relates to a myocardial cell cryopreservation kit containing the composition, a method for the cryopreservation of mammal myocardial cells by means of using the composition above, and the use of the composition above in the preparation of a reagent for the cryopreservation of mammal myocardial cells.

A method for preserving a tissue graft includes submerging the tissue graft in a solution containing one or more antimicrobial and/or stabilizing agents and storing the tissue graft in the solution for a period of time of at least 24 hours while the solution is in an unfrozen state. A tissue preservation system includes a solution containing one or more antimicrobial and/or stabilizing agents and a tissue graft in the solution.

Compositions and Methods for Stabilizing Circulating Tumor Cells Methods and compositions for stabilizing a biological sample for analysis, comprising the steps of obtaining in a sample collection device a biological sample from a subject, especially blood, the biological sample including at least one circulating tumor cell from the subject. The methods may include a step of contacting the biological sample with a protective agent composition that includes a preservative agent, an optional anticoagulant, and a quenching agent to form a mixture that includes the protective agent composition and the sample.

The present disclosure relates to carbon dioxide permeable containers for storing blood and methods for the improved preservation of whole blood and blood components. The improved devices and methods for the collection of blood and blood components provide for whole blood and blood components having reduced levels of carbon dioxide and the elimination of the plasticizer DEHP. The devices and methods provide for the preparation of carbon dioxide depleted blood and blood components for storage that improves the overall quality of the transfused blood and improves health outcomes inpatients and reduces risks associated with DEHP. The devices and methods also provide for maintenance of low oxygen content in blood and blood components during storage. Compositions comprising a blood product and an additive solution are also disclosed.

A repaired ex vivo organ suitable for transplantation in a human, said repaired ex vivo organ having undergone ex vivo organ perfusion for a maintenance period, wherein said organ had been assessed as being unsuitable for transplantation into a human before the maintenance period and was determined to be suitable for transplantation after the maintenance period.

Provided herein are formulations and methods for the stabilization of one or more thrombocytes at ambient temperatures. Also provided are formulations and methods for the stabilization of one or more thrombocytes in an inactivated state in a blood sample at ambient temperatures. Further provided are articles of manufacture and kits and methods for substantially stable storage of one or more thrombocyte at ambient temperatures.

The invention provides a process for the preparation of cyclosporin derivatives.

Methods for extending the shelf life of donor blood and/or red blood cells (RBC) with a cyclodextrin composition are described. The cyclodextrin composition contains at least one cyclodextrin complexed with at least one exogenous lipid. Also described are such treated donor blood and/or RBC.

Disclosed are viable cell compositions and related methods of preparation, maintenance and use. The viable cell composition can contain specified levels of cells, hydroxyethyl starch, and dimethylsulfoxide, and can be cryopreserved. The cryopreserved form of the composition can be thawed and combined with an aqueous liquid diluting medium to prepare a diluted viable cell composition that can contain specified, reduced levels of the dimethylsulfoxide and hydroxyethyl starch. The diluting medium can contain trehalose. The prepared, diluted viable cell composition can be administered to a patient.

A system and methodology for the preservation of red blood cells is described in which red blood cells are oxygen or oxygen and carbon dioxide depleted, treated and are stored in an anaerobic environment to optimize preparation for transfusion. More particularly, a system and method for extended storage of red blood cells from collection to transfusion that optimizes red blood cells prior to transfusion is described.